World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
52127
World Ranking
9868
National Ranking
5074

James Christensen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James Christensen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 285 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James Christensen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James Christensen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James Christensen is affiliated with Pfizer in the United States and has a research focus primarily in the fields of medicine and biochemistry, genetics, and molecular biology. Their publications cover a wide range of topics in molecular biology, oncology, pulmonary and respiratory medicine, cancer research, and immunology.

The scientist's main topics of work include:

  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • Protein Kinase Regulation and GTPase Signaling
  • Cancer-related gene regulation
  • PI3K/AKT/mTOR signaling in cancer
  • Protein Tyrosine Phosphatases
  • Cancer Treatment and Pharmacology

Frequently collaborating coauthors with Christensen are:

  • Peter Olson
  • Jill Hallin
  • David M. Briere
  • Matthew A. Marx
  • Lars D. Engstrom

Christensen has contributed publications to several prominent venues, with many appearing in:

  • Cancer Research
  • Journal of Clinical Oncology
  • Molecular Cancer Research
  • Journal of Medicinal Chemistry
  • Cancer Discovery

Some of the recent papers authored or coauthored by Christensen include:

  • "Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation," 2022, New England Journal of Medicine
  • "Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor," 2021, Journal of Medicinal Chemistry
  • "Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer," 2020, Journal of Medicinal Chemistry
  • "Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor," 2022, Nature Medicine
  • "Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C," 2022, New England Journal of Medicine

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship

    Dirk B. Mendel;A. Douglas Laird;Xiaohua Xin;Sharianne G. Louie

  • Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

    John M.L. Ebos;Christina R. Lee;William Cruz-Munoz;Georg A. Bjarnason

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

    J. Jean Cui;Michelle Tran-Dubé;Hong Shen;Mitchell Nambu

  • The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

    Jill Hallin;Lars D. Engstrom;Lauren Hargis;Andrew Calinisan

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

    James G. Christensen;Jon Burrows;Ravi Salgia

  • An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

    Helen Y. Zou;Qiuhua Li;Joseph H. Lee;Maria E. Arango

  • Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

    James G Christensen;Helen Y Zou;Maria E Arango;Qiuhua Li

  • Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

    Gromoslaw A. Smolen;Raffaella Sordella;Beth Muir;Gayatry Mohapatra

  • c-Met: Structure, functions and potential for therapeutic inhibition

    Patrick C. Ma;Gautam Maulik;Gautam Maulik;James Christensen;Ravi Salgia;Ravi Salgia

  • A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

    Takaaki Sasaki;Jussi Koivunen;Atsuko Ogino;Masahiko Yanagita

  • Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

    Patrick C. Ma;Ramasamy Jagadeeswaran;Simha Jagadeesh;Maria S. Tretiakova

  • A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

    James G. Christensen;Randall Schreck;Jon Burrows;Poonam Kuruganti

  • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

    Mark Magdi Awad;Geoffrey Raymond Oxnard;David M Jackman;Daniel O. Savukoski

  • Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

    Sai Hong Ignatius Ou;Eunice L. Kwak;Christina Siwak-Tapp;Joni Dy

  • Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

    Ultan McDermott;A. John Iafrate;Nathanael S. Gray;Toshi Shioda

Frequent Co-Authors

Pasi A. Jänne
Pasi A. Jänne Harvard University
Ravi Salgia
Ravi Salgia City Of Hope National Medical Center
Shengyun Fang
Shengyun Fang University of Maryland, Baltimore
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Carleen Cullinane
Carleen Cullinane Peter MacCallum Cancer Centre
Yael P. Mosse
Yael P. Mosse Children's Hospital of Philadelphia
A. John Iafrate
A. John Iafrate Harvard University
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Nathanael S. Gray
Nathanael S. Gray Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring a career in medicine but seeking flexible or alternative pathways, online degrees in nursing can be an excellent option. These programs allow you to study remotely while balancing personal and professional commitments. There are many cheapest online bsn programs available, enabling you to earn a Bachelor of Science in Nursing at a lower cost.

For registered nurses aiming to enhance their qualifications, enrolling in one of the cheapest online rn to bsn programs is a practical step toward career advancement and increased earning potential. If you are interested in specialized or leadership roles, an advanced degree such as a online nursing doctorate provides opportunities for research, teaching, or executive positions.

For those holding a non-nursing bachelor's degree and seeking a fast career change, direct entry online msn programs are designed to help you become a registered nurse with a Master of Science in Nursing in a shorter time frame. These diverse online pathways make it easier to enter or advance in the medical field from almost anywhere.

Best Scientists Citing James Christensen

Trending Scientists

Recently Published Articles